<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Insulin Glargine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00047</strong>&#160; (BIOD00045, BTD00045, DB01308)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Insulin glargine is produced by recombinant <span class="caps">DNA</span> technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00047.png?1266600387"><img alt="Db00047" src="/system/protein_structures/thumb/DB00047.png?1266600387"></a></td></tr><tr><th>Protein chemical formula</th><td>C<sub>267</sub>H<sub>404</sub>N<sub>72</sub>O<sub>78</sub>S<sub>6</sub> </td></tr><tr><th>Protein average weight</th><td>6063 Daltons </td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;A chain
GIVEQCCTSICSLYQLENYCG</pre><pre class="sequence">&gt;B chain
FVNQHLCGSHLVEALYLVCGERGFFYTPKTRR</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00047/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Insulin Glargine (rDNA origin)</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Lantus</td><td>Sanofi-Aventis</td></tr><tr><td>Lantus OptiSet </td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lantus SoloStar</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypoglycemic-agents">Hypoglycemic Agents</a></li>
<li><a href="/mesh/antidiabetic-agents">Antidiabetic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>160337-95-1</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of Type 1 or 2 diabetes mellitus in patients over 17 years old who require a long-acting (basal) insulin for the control of hyperglycemia. May be used in pediatric patients with Type 1 diabetes mellitus who require a long-acting (basal) insulin for glycemic control.  </td></tr><tr><th>Pharmacodynamics</th><td>Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin glargine is a long-acting insulin analogue with a flat and predictable action profile. It is used to mimic the basal levels of insulin in diabetic individuals. The onset of action of insulin glargine is approximately 90 minutes and its duration of action is up to 24 hours. The action profile of insulin glargine is peakless. The significance of this finding is that insulin glargine has a lower chance of nocturnal hypoglycemia. </td></tr><tr><th>Mechanism of action</th><td>Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body. </td></tr><tr><th>Absorption</th><td>Because of the modifications to the A and B chain, the isoelectric point shifts towards a neutral pH and insulin glargine is more stable in acidic conditions than regular insulin. As insulin glargine is less soluble at neutral pH, once injected, forms microprecipitates. Slow release of insulin glargine from microprecipitates provides a relatively constant concentration of insulin over 24 hours. Onset of action is approximately 1.1 hours. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Partly metabolized to two active metabolites with similar <i>in vitro</i> activity to insulin: A21-Gly-insulin and A21-Gly-des-B30-Thr-insulin. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Insulin Glargine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00786">A21-Gly-des-B30-Thr-insulin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/807">Details</a></td></tr><tr><td>Insulin Glargine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00787">A21-Gly-insulin</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/808">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Not reported in humans; 30 hours <i>in vitro</i> in mammalian reticulocytes.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Other adverse events that may occur include allergic reaction, injection site reaction, lipodystrophy, pruritis, and rash.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Gruppo Lepetit SPA</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Subcutaneous</td><td>100 units/ml</td></tr></tbody></table></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00195">Betaxolol</a></td><td>The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01295">Bevantolol</a></td><td>The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>The beta-blocker, carteolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>The beta-blocker, labetolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>The beta-blocker, nadolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>The beta-blocker, pindolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01297">Practolol</a></td><td>The beta-blocker, practolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>The beta-blocker, propranolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00052">Somatropin recombinant</a></td><td>Somatropin may antagonize the hypoglycemic effect of insulin glargine. Monitor for changes in fasting and postprandial blood sugars. </td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>The beta-blocker, sotalol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>The beta-blocker, timolol, may decrease symptoms of hypoglycemia.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>